This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 28.57% and 8.33%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Exact Sciences (EXAS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Exact Sciences (EXAS) stock based on the movements in the options market lately.
Exact Sciences (EXAS) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer Amends Xtandi Study Protocols to Speed Up Completion
by Zacks Equity Research
Pfizer (PFE) and Astellas Pharma announce amendment of protocols for two phase III studies evaluating Xtandi in hormone-sensitive prostate cancer, advancing anticipated completion date.
Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer
by Zacks Equity Research
Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.
Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher
by Zacks Equity Research
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for VTWG
Is the Options Market Predicting a Spike in Exact Sciences (EXAS) Stock?
by Zacks Equity Research
Surging implied volatility makes Exact Sciences (EXAS) stock lucrative to the option traders.
Why Earnings Season Could Be Great for Exact Sciences (EXAS)
by Zacks Equity Research
Exact Sciences (EXAS) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.
Exact Sciences (EXAS) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
The shares of Exact Sciences (EXAS) rose over 5% yesterday.
Zacks Market Edge Highlights: Boeing, Exact Sciences, CBOE Global Markets, CME Group and Nvidia
by Zacks Equity Research
Zacks Market Edge Highlights: Boeing, Exact Sciences, CBOE Global Markets, CME Group and Nvidia
Why We Are Obsessed with Bitcoin
by Tracey Ryniec
Tulips, the South Sea, Gold, Dot-coms, Real Estate: Is Bitcoin just another in a long line of manias?
Anatomy of Success: Exact Sciences Corp (EXAS)
by Brian Hamilton
By utilizing the Zacks Rank system, you can uncover companies with extraordinary growth potential.
Exact Sciences (EXAS) Looks Good: Stock Adds 9.8% in Session
by Zacks Equity Research
Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.
What's in the Cards for Geron (GERN) this Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q3 release.
What to Expect From Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme (EPZM) is a development-stage company, with no approved products in its portfolio. Hence, investor focus is expected to remain on the company's pipeline updates and mainly on its lead candidate, tazemetostat.
Get Ready To Be Surprised This Earnings Season
by Kevin Matras
Kevin Matras details a good screen to use before and after a company reports this earnings season. Highlighted stocks include EXAS, MOD, B, OC and HIIQ.
Zacks.com featured highlights include Nintendo Co., Exact Sciences, Tabula Rasa Healthcare, Facebook and Nova Measuring Instruments
by Zacks Equity Research
Zacks.com featured highlights include Nintendo Co., Exact Sciences, Tabula Rasa Healthcare, Facebook and Nova Measuring Instruments
Inovio Initiates Bladder Cancer Study With Roche's Tecentriq
by Zacks Equity Research
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
5 Top-Ranked Profitable Stocks to Boost Your Portfolio
by Zacks Equity Research
Profitability analysis is used to measure the company's ability to manage its revenues effectively and provide stunning returns to its investors.
Shire's New Formulation of Oncaspar Gets CHMP Recommendation
by Zacks Equity Research
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.
MiMedx Group (MDXG) Looks Good: Stock Adds 5.4% in Session
by Zacks Equity Research
MiMedx Group (MDXG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Pluristem Therapeutics Inc. (PSTI) Catches Eye: Stock Jumps 5.1%
by Zacks Equity Research
Pluristem Therapeutics Inc. (PSTI) saw its shares rise over 5% on the day.